James M. D'rozario

Garran, ACT, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Journal: Blood
Published: March 28, 2023

Incidence of chronic renal injury in patients undergoing autologous stem cell transplant therapy.

Incidence of chronic renal injury in patients undergoing autologous stem cell transplant therapy.

Journal: Internal medicine journal
Published: December 14, 2021

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Journal: Blood
Published: December 01, 2021

Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.

Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.

Journal: Immunotherapy
Published: November 08, 2021

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL.

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL.

Journal: Blood advances
Published: June 21, 2021

The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.

The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: April 26, 2021

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).

Journal: Haematologica
Published: February 24, 2021

Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.

Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.

Journal: Internal medicine journal
Published: February 03, 2021

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 28, 2020

GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial.

GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial.

Journal: Pharmacology research & perspectives
Published: May 02, 2019

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Journal: Annals of hematology
Published: January 09, 2019

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL.

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL.

Journal: Therapeutic advances in hematology
Published: September 08, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026